Idelalisib Completed Phase 1 Trials for Relapsed/Refractory Mantle Cell Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01838434Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma